EpiVax, Inc. - Informatics and Immunology
  • Our Company
    • Company Overview
    • Corporate Responsibility
    • Mission, Vision & Values
    • Team
    • Careers
    • Contact Us
  • Pipeline
    • Pipeline Overview
    • BioDefense Vaccines
    • Tregitope: Immunomodulation Power Tool
    • Deimmunization Projects
  • Vaccine Services
    • Vaccine Services
    • iVAX: Web-based Vaccine Design
    • PreVAX Analysis
    • EpiCC
  • Immunogenicity Assessment
    • Immunogenicity Assessment Overview
    • ISPRI Web-based Immunogenicity Assessment
    • PreDeFT Analysis
    • High Throughput Immunogenicity Analysis
    • PANDA Screening
    • ISPRI for Host Cell Proteins
    • Deimmunization
    • Trusted Expert Advice (TEA) Consulting Services
  • Lab Services
    • Lab Services Overview
    • HLA Binding Assays
    • T Cell Assays
  • Press Room
    • Press Room
    • Events
      • Webinars
    • Publication & Poster Search
    • Client Testimonials
    • Thinking Out Loud (Blog)
    • Recipes For Success (Podcast)
  • Contact Us
Select Page
Bioinformatics tools for identifying class I-restricted epitopes

Bioinformatics tools for identifying class I-restricted epitopes

by epivax3 | Oct 22, 2016

Methods (Epitope Mapping Issue). Bill Kwok, editor, Methods 29 (2003) 289–298.
T Cell Epitope Identification for Bovine Vaccines: An Epitope Mapping Method for BoLA A-11

T Cell Epitope Identification for Bovine Vaccines: An Epitope Mapping Method for BoLA A-11

by epivax3 | Oct 22, 2016

International Journal for Parasitology (Thematic Issue on Vaccines, David Brake Editor, (Vol 33/5-6 pp 641-653). 2003.
Greater CD8+ TCR heterogeneity and functional flexibility in HIV-2 compared to HIV-1 infection

Greater CD8+ TCR heterogeneity and functional flexibility in HIV-2 compared to HIV-1 infection

by epivax3 | Oct 22, 2016

J Immunol. 2003 Jul 1; 171(1):307-16.
Mapping Cross-Clade HIV-1 Vaccine Epitopes Using a Bioinformatics Approach

Mapping Cross-Clade HIV-1 Vaccine Epitopes Using a Bioinformatics Approach

by epivax3 | Oct 22, 2016

Vaccine 21 (2003) 4486–4504. https://www.sciencedirect.com/science/journal/0264410X.

Recent Posts

  • Dreaming of Peptides (and Hello from Tokyo!)
  • Streamlining Generic Drug Immunogenicity Evaluation: EpiVax’s “PANDA” Approach
  • Throw Down a Challenge
  • EpiVax Birthday Cake Alert! | Fall ’23 Travel Schedule
  • Lab Day at the Beach 2023 *Pictures!*

Categories

  • EpiVax Immunoncology
  • Events
  • Featured
  • News
  • Recipes for Success – Vlog
  • Thinking Out Loud -Blog
  • Uncategorized
  • Webinars

Discover

  • Vaccine Services
  • Immunogenicity Assessment
  • Deimmunization
  • Lab Services
  • Pipeline

About

  • Our Company
  • Press Room
  • Events
  • Publication & Poster Search
  • Thinking Out Loud (Blog)
  • Contact Us

Connect

© 2023 EpiVax, Inc. – Informatics and Immunology, All rights reserved. Privacy Policy • 188 Valley Street, Suite 424, Providence, RI 02909 • ph: 401.272.2123 • fax: 401.272.7562